Evidence map›Paper›PMID 36508048›Full record

ArticleClinical and experimental medicine2023

Use of remdesivir for COVID-19 in patients with hematologic cancer.

Alexandra Martin-Onraët, Corazón Barrientos-Flores, Diana Vilar-Compte, Carolina Pérez-Jimenez, Pamela Alatorre-Fernandez

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Alexandra Martin-OnraëtInfectious Diseases Department, Instituto Nacional de Cancerología, Avenida San Fernando 22, Col Sección 16 Belisario Dominguez, 14080, Tlalpan CDMX, Mexico. alexitemaon@gmail.com.ORCID https://orcid.org/0000-0002-8627-404X
Corazón Barrientos-FloresInfectious Diseases Department, Instituto Nacional de Cancerología, Avenida San Fernando 22, Col Sección 16 Belisario Dominguez, 14080, Tlalpan CDMX, Mexico.
Diana Vilar-CompteInfectious Diseases Department, Instituto Nacional de Cancerología, Avenida San Fernando 22, Col Sección 16 Belisario Dominguez, 14080, Tlalpan CDMX, Mexico.ORCID https://orcid.org/0000-0001-8564-8735
Carolina Pérez-JimenezInfectious Diseases Department, Instituto Nacional de Cancerología, Avenida San Fernando 22, Col Sección 16 Belisario Dominguez, 14080, Tlalpan CDMX, Mexico.ORCID https://orcid.org/0000-0002-0212-9436
Pamela Alatorre-FernandezInfectious Diseases Department, Instituto Nacional de Cancerología, Avenida San Fernando 22, Col Sección 16 Belisario Dominguez, 14080, Tlalpan CDMX, Mexico.ORCID https://orcid.org/0000-0002-8873-8573
Instituto Nacional de Cancerología · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposesPatients with hematologic malignancies (HM) are among the individuals with highest risk of COVID-19 complications. We report the impact of remdesivir in patients with hematologic malignancies (HM) during Omicron in Mexico City.

methodsAll patients with HM and COVID-19 during December 2021-March 2022 were included. Socio-demographic and clinical data were collected. The primary outcome was COVID-19 progression. Variables associated with progression were analyzed.

results115 patients were included. Median age was 50 years (IQR 35-63); 36% (N = 41) had at least one comorbidity. Fifty-two percent had non-Hodgkin lymphoma. Fifty patients (44%) had at least two doses of SARS-CoV-2 vaccine. COVID-19 was classified as mild (52.6%), moderate (9.7%), and severe/critical (28%). Twenty-eight patients (24%) received remdesivir. Nine patients received remdesivir at the ambulatory clinic (33%), the rest during hospital admission. Overall, 22(19%) patients progressed to severe/critical COVID-19; nine died due to COVID-19(8%). Hospital admission for non-COVID-19 causes was associated with higher odds of progression. Remdesivir did not reduce the risk of progression in hospitalized patients; none of the patients who received remdesivir in the ambulatory clinic progressed to severe COVID-19 or died.

conclusionsPatients with HM and COVID-19 continue to present with high risk of complications. More prospective studies are needed to define the impact of antivirals in this high-risk group, including the best duration of treatment. Also, better vaccine coverage and access to treatment are mandatory.

Indexed as

Antiviral AgentsCOVID-19COVID-19 Drug TreatmentHematologic NeoplasmsAdenosine MonophosphateAlanineCOVID-19 VaccinesHumansMiddle AgedSARS-CoV-2Adenosine MonophosphateAlanineAntiviral AgentsCOVID-19 VaccinesremdesivirCOVID-19Hematologic malignanciesOmicronRemdesivir

Identifiers

PMID36508048
PMCPMC9744041
OpenAlexW4312064983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.